

Abraham Pinter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3957628/publications.pdf>

Version: 2024-02-01

53
papers

2,934
citations

172386

29
h-index

182361

51
g-index

63
all docs

63
docs citations

63
times ranked

2983
citing authors

#	ARTICLE	IF	CITATIONS
1	Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 32.	2.3	7
2	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. <i>Nature Communications</i> , 2022, 13, 462.	5.8	17
3	SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States. <i>JAMA Network Open</i> , 2021, 4, e212816.	2.8	28
4	Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms. <i>Viruses</i> , 2021, 13, 953.	1.5	17
5	Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. <i>Viruses</i> , 2021, 13, 1246.	1.5	35
6	Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-stimulated T Cell IFN- γ and TNF- α Production. <i>Journal of Immunology</i> , 2021, 207, 436-448.	0.4	1
7	Field evaluation of a prototype tuberculosis lipoarabinomannan lateral flow assay on HIV-positive and HIV-negative patients. <i>PLoS ONE</i> , 2021, 16, e0254156.	1.1	3
8	CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro. <i>Frontiers in Immunology</i> , 2021, 12, 652223.	2.2	27
9	Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2021, 224, 1345-1356.	1.9	22
10	Association of Varying Clinical Manifestations and Positive Anti-SARS-CoV-2 IgG Antibodies: A Cross-Sectional Observational Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3331-3338.e2.	2.0	9
11	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. <i>Journal of Immunological Methods</i> , 2021, 499, 113165.	0.6	6
12	Prevalence and Correlates of SARS CoV-2 Among a Community-Based Sample Recruited Using Randomized Venue-Based Sampling. Essex County, NJ, 2020. <i>Journal of Racial and Ethnic Health Disparities</i> , 2021, , 1.	1.8	0
13	Robust IgM responses following intravenous vaccination with Bacille Calmette-Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques. <i>Nature Immunology</i> , 2021, 22, 1515-1523.	7.0	55
14	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. <i>Frontiers in Immunology</i> , 2021, 12, 787603.	2.2	1
15	Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. <i>Scientific Reports</i> , 2020, 10, 13944.	1.6	8
16	Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. <i>Journal of Clinical Investigation</i> , 2020, 130, 5756-5764.	3.9	53
17	Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 852-861.	4.6	159
18	Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients. <i>PLoS ONE</i> , 2019, 14, e0215443.	1.1	51

#	ARTICLE	IF	CITATIONS
19	Surface-enhanced resonance Raman scattering for the sensitive detection of a tuberculosis biomarker in human serum. <i>Journal of Raman Spectroscopy</i> , 2019, 50, 15-25.	1.2	19
20	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	1.5	46
21	Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of <i>Mycobacterium tuberculosis</i> , and Complexity of Antibody Specificities toward This Antigen. <i>Journal of Immunology</i> , 2018, 200, 3053-3066.	0.4	58
22	Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. <i>Journal of Virology</i> , 2018, 92, .	1.5	8
23	A Novel Sensitive Immunoassay Targeting the 5-Methylthio- α -Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	95
24	Detection of lipoarabinomannan in urine and serum of HIV-positive and HIV-negative TB suspects using an improved capture-enzyme linked immuno absorbent assay and gas chromatography/mass spectrometry. <i>Tuberculosis</i> , 2018, 111, 178-187.	0.8	48
25	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
26	Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. <i>PLoS ONE</i> , 2017, 12, e0180245.	1.1	20
27	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017, 12, e0180720.	1.1	55
28	Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. <i>PLoS Computational Biology</i> , 2016, 12, e1005094.	1.5	17
29	DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques. <i>PLoS ONE</i> , 2014, 9, e91550.	1.1	42
30	Identification of Key Determinants for the Unusual Neutralization Sensitivity of the MW965.26 Env. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A209-A209.	0.5	0
31	Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. <i>Virology</i> , 2014, 448, 363-374.	1.1	8
32	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	1.1	248
33	Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies. <i>PLoS ONE</i> , 2014, 9, e89987.	1.1	8
34	Vaccination with Vaxfectin [®] adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2069-2080.	1.4	12
35	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. <i>Journal of Virology</i> , 2011, 85, 3128-3141.	1.5	151
36	Characterization of Structural Features and Diversity of Variable-Region Determinants of Related Quaternary Epitopes Recognized by Human and Rhesus Macaque Monoclonal Antibodies Possessing Unusually Potent Neutralizing Activities. <i>Journal of Virology</i> , 2011, 85, 10730-10740.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. <i>Virology</i> , 2010, 404, 59-70.	1.1	30
38	Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. <i>Virology</i> , 2010, 405, 513-523.	1.1	42
39	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. <i>Journal of Virology</i> , 2009, 83, 1240-1259.	1.5	67
40	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. <i>Virology</i> , 2009, 387, 414-426.	1.1	86
41	Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. <i>Molecular Immunology</i> , 2009, 46, 917-926.	1.0	107
42	Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. <i>Virology</i> , 2008, 372, 233-246.	1.1	53
43	Roles of HIV-1 Env Variable Regions in Viral Neutralization and Vaccine Development. <i>Current HIV Research</i> , 2007, 5, 542-553.	0.2	33
44	Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 6865-6872.	1.5	113
45	Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 7127-7135.	1.5	83
46	Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking. <i>Journal of Virology</i> , 2005, 79, 780-790.	1.5	82
47	The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates. <i>Journal of Virology</i> , 2005, 79, 6909-6917.	1.5	37
48	The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. <i>Journal of Virology</i> , 2004, 78, 2394-2404.	1.5	111
49	The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection. <i>Journal of Virology</i> , 2004, 78, 5205-5215.	1.5	236
50	Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci. <i>Journal of Immunology</i> , 2002, 169, 595-605.	0.4	61
51	Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades. <i>Journal of Virology</i> , 2002, 76, 9035-9045.	1.5	172
52	V3-Specific Polyclonal Antibodies Affinity Purified from Sera of Infected Humans Effectively Neutralize Primary Isolates of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1737-1748.	0.5	55
53	A Potent, Neutralizing Human Monoclonal Antibody against a Unique Epitope Overlapping the CD4-Binding Site of HIV-1 gp120 That Is Broadly Conserved across North American and African Virus Isolates. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 985-996.	0.5	45